Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1362531rdf:typepubmed:Citationlld:pubmed
pubmed-article:1362531lifeskim:mentionsumls-concept:C0036078lld:lifeskim
pubmed-article:1362531lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:1362531lifeskim:mentionsumls-concept:C0439230lld:lifeskim
pubmed-article:1362531pubmed:issue4lld:pubmed
pubmed-article:1362531pubmed:dateCreated1993-2-24lld:pubmed
pubmed-article:1362531pubmed:abstractTextWe report a 53-year-old man with sero-negative rheumatoid arthritis who developed a fever, rash and hepatitis 3 weeks after starting sulphasalazine therapy. This was associated with a T cell lymphocytosis, eosinophilia and evidence of classical complement pathway activation. He responded to high dose corticosteroids. This is a rare but characteristic reaction which is likely to be encountered by rheumatologists more frequently with the increasing use of sulphasalazine. It should be recognized promptly as it may be fatal and can be confused with other systemic diseases.lld:pubmed
pubmed-article:1362531pubmed:languageenglld:pubmed
pubmed-article:1362531pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1362531pubmed:citationSubsetIMlld:pubmed
pubmed-article:1362531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1362531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1362531pubmed:statusMEDLINElld:pubmed
pubmed-article:1362531pubmed:monthDeclld:pubmed
pubmed-article:1362531pubmed:issn0770-3198lld:pubmed
pubmed-article:1362531pubmed:authorpubmed-author:BrooksHHlld:pubmed
pubmed-article:1362531pubmed:authorpubmed-author:NicholF EFElld:pubmed
pubmed-article:1362531pubmed:authorpubmed-author:TaylorH GHGlld:pubmed
pubmed-article:1362531pubmed:issnTypePrintlld:pubmed
pubmed-article:1362531pubmed:volume11lld:pubmed
pubmed-article:1362531pubmed:ownerNLMlld:pubmed
pubmed-article:1362531pubmed:authorsCompleteYlld:pubmed
pubmed-article:1362531pubmed:pagination566-8lld:pubmed
pubmed-article:1362531pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:meshHeadingpubmed-meshheading:1362531-...lld:pubmed
pubmed-article:1362531pubmed:year1992lld:pubmed
pubmed-article:1362531pubmed:articleTitleThe three week sulphasalazine syndrome.lld:pubmed
pubmed-article:1362531pubmed:affiliationDepartment of Rheumatology, Leicester Royal Infirmary, United Kingdom.lld:pubmed
pubmed-article:1362531pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1362531pubmed:publicationTypeCase Reportslld:pubmed